Alumis Inc.
ALMS
Ранг среди акций
#9807
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Цена акции
$6.78
Последняя синхронизация: 2026-10-21
Рыночная капитализация
$877.57M
Изменение (1 день)
1.19%
Изменение (1 год)
198.68%
Страна
US
Торговля Alumis Inc. (ALMS)
Категория
Healthcare
История цены акций Alumis Inc. (ALMS)
Наивысшая цена закрытия: $2.34 2025-05-01
Наименьшая цена закрытия: $21.58 2023-05-01
Наименьшая цена закрытия: $21.58 2023-05-01
История цены акций Alumis Inc. с 2023 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2025 | -35.06% |
| 2024 | -49.49% |
| 2023 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
